9
1
o
(1.20 g, yield 75%) H NMR (300 MHz, CDCl3, 25 C): δ =
3.69 (s, 3H, CH2C6H4(OCH3)-4); 3.73 (s, 3H, CH2C6H4(OCH3)-
3); 5.73 (s, 2H, CH2C6H4(OCH3)-4); 5.76 (s, 2H,
CH2C6H4(OCH3)-3); 6.78-7.54 (m, 12H, arom. CHs, NC6H4N,
CH2C6H4(OCH3)-3 and CH2C6H4(OCH3)-4); 12.09 (s, 1H,
NCHN) ppm. 13C NMR (75 MHz, CDCl3, 25 oC): δ = 50.2
Pd(OAc)2 (0.50 mmol) in degassed DMSO (3 mL) was heated
ACCEPTED MANUSCRIPT
with vigorous stirring at 100 oC for 24 h. Volatiles were removed
in vacuo, and the residue was washed with n-pentane (2×5 mL).
The crude product was dissolved with CH2Cl2 then filtered
through a pad of celite and silica gel to remove the unreacted
Pd(OAc)2 and benzimidazolium chloride. Next, the crude
complex was crystallized from dichloromethane/diethyl ether
mixture (1:2, v/v) at room temperature and, completely dried
under vacuum. All palladium complexes were isolated as air- and
moisture-stable yellow solids and were isolated in 40-59% yields.
(CH2C6H4(OCH3)-4);
50.5
(CH2C6H4(OCH3)-3);
54.3
(CH2C6H4(OCH3)-4); 54.6 (CH2C6H4(OCH3)-3); 112.7, 112.8,
113.7, 119.3, 123.7, 126.0, 126.1, 129.0, 129.4, 130.2, 130.4,
133.1, 159.2, 159.3 (arom. Cs, NC6H4N, CH2C6H4(OCH3)-3 and
CH2C6H4(OCH3)-4); 142.9 (NCHN) ppm. Elemental analysis
calcd (%) for C23H23ClN2O2 (Mr = 394.90): C 69.95, H 5.87, N
7.09; found (%): C 69.97, H 5.88, N 7.11.
4.3.1. cis/trans-Dichloro-bis[1-(3-methoxybenzyl)-3-(4-chloro-
benzyl)benzimidazol-2-ylidene]palladium(II) (2a)
(0.234 g, yield 52%) 1H NMR (400 MHz, CDCl3, 25 oC): δ =
3.69 and 3.70 (s, 6H, CH2C6H4(OCH3)-3); 5.26 and 5.29 (s, 4H,
CH2C6H4(Cl)-4); 6.20 and 6.23 (s, 4H, CH2C6H4(OCH3)-3); 6.80-
7.59 (m, 24H, arom. CHs, NC6H4N, CH2C6H4(OCH3)-3 and
4.2.5.
1-(3-Methoxybenzyl)-3-(2,3,5,6-tetramethylbenzyl)benz-
imidazolium Chloride (1e)
1
o
(1.64 g, yield 93%) H NMR (300 MHz, CDCl3, 25 C): δ =
2.18 and 2.19 (s, 12H, CH2C6H(CH3)4-2,3,5,6); 3.72 (s, 3H,
CH2C6H4(OCH3)-3); 5.83 (s, 2H, CH2C6H(CH3)4-2,3,5,6); 5.84
(s, 2H, CH2C6H4(OCH3)-3); 6.76-7.51 (m, 9H, arom. CHs,
NC6H4N, CH2C6H4(OCH3)-3 and CH2C6H(CH3)4-2,3,5,6); 11.42
o
CH2C6H4(Cl)-4) ppm. 13C NMR (100 MHz, CDCl3, 25 C): δ =
52.7 and 52.8 (CH2C6H4(Cl)-4); 52.9 and 53.0 (CH2C6H4(OCH3)-
3); 55.6 and 55.7 (CH2C6H4(OCH3)-3); 111.3, 111.4, 112.5,
112.6, 114.5, 114.7, 120.2, 120.3, 123.0, 127.8, 127.9, 128.7,
128.8, 129.5, 134.8, 135.4, 135.5, 137.0, 137.1, 160.0, 160.1
(arom. Cs, NC6H4N, CH2C6H4(OCH3)-3 and CH2C6H4(Cl)-4);
182.3 and 182.5 (Pd-Ccarbene) ppm. Elemental analysis calcd (%)
for C44H38Cl4N4O2Pd (Mr = 903.00): C 58.52, H 4.24, N 6.20;
found (%): C 58.54, H 4.26, N 6.22.
(s, 1H, NCHN) ppm. 13C NMR (75 MHz, CDCl3, 25 C): δ =
o
16.2 and 20.6 (CH2C6H(CH3)4-2,3,5,6); 47.9 (CH2C6H(CH3)4-
2,3,5,6); 51.5 (CH2C6H4(OCH3)-3); 55.6 (CH2C6H4(OCH3)-3);
113.6, 113.8, 114.7, 120.1, 127.0, 127.6, 130.3, 131.6, 133.4,
133.6, 134.1, 134.5, 135.0, 135.1, 160.2 (arom. Cs, NC6H4N,
CH2C6H4(OCH3)-3 and CH2C6H(CH3)4-2,3,5,6); 143.9 (NCHN)
ppm. Elemental analysis calcd (%) for C26H29ClN2O (Mr =
421.00): C 74.18, H 6.94, N 6.65; found (%): C 74.20, H 6.95, N
6.67.
4.3.2.
cis/trans-Dichloro-bis[1-(3-methoxybenzyl)-3-(n-butyl)
benzimidazol-2-ylidene]palladium(II) (2b)
(0.203 g, yield 53%) 1H NMR (300 MHz, CDCl3, 25 oC): δ =
3
0.72 and 1.01 (t, J = 7.4 Hz, 6H, CH2CH2CH2CH3); 1.22 and
4.2.6. 1-(3-Methoxybenzyl)-3-(4-phenoxybutyl)benzimidazolium
Chloride (1f)
3
1.53 (hext, J = 7.6 Hz, 4H, CH2CH2CH2CH3); 2.06 and 2.21
3
(pent, J = 7.6 Hz, 4H, CH2CH2CH2CH3); 3.56 and 3.68 (s, 6H,
1
o
(1.46 g, yield 82%) H NMR (500 MHz, CDCl3, 25 C): δ =
1.97 (pent, 3J = 5.8 Hz, 2H, CH2CH2CH2CH2OC6H5); 2.32 (pent,
3J = 7.3 Hz, 2H, CH2CH2CH2CH2OC6H5); 3.78 (s, 3H,
CH2C6H4(OCH3)-3); 4.68 and 4.79 (t, 3J = 7.8 Hz, 4H,
CH2CH2CH2CH3); 5.90 and 6.07 (s, 4H, CH2C6H4(OCH3)-3);
6.65-7.32 (m, 16H, arom. CHs, NC6H4N and CH2C6H4(OCH3)-3)
o
CH2C6H4(OCH3)-3); 4.04 (t, 3J
CH2CH2CH2CH2OC6H5); 4.75 (t, 3J
=
5.8 Hz, 2H,
7.3 Hz, 2H,
ppm. 13C NMR (75 MHz, CDCl3, 25 C): δ = 13.7 and 14.0
=
(CH2CH2CH2CH3); 20.4 and 20.7 (CH2CH2CH2CH3); 31.8 and
31.9 (CH2CH2CH2CH3); 48.3 and 48.4 (CH2CH2CH2CH3); 52.8
and 53.2 (CH2C6H4(OCH3)-3); 55.6 and 55.8 (CH2C6H4(OCH3)-
3); 110.3, 110.4, 111.4, 111.5, 112.5, 112.6, 114.4, 114.8, 120.2,
122.8, 122.9, 129.4, 129.7, 134.3, 134.6, 134.9, 135.0, 137.1,
137.2, 160.0, 160.3 (arom. Cs, NC6H4N and CH2C6H4(OCH3)-3);
181.7 and 181.8 (Pd-Ccarbene) ppm. Elemental analysis calcd (%)
for C38H44Cl2N4O2Pd (Mr = 766.10): C 59.57, H 5.79, N 7.31;
found (%): C 59.59, H 5.80, N 7.33.
CH2CH2CH2CH2OC6H5); 5.84 (s, 2H, CH2C6H4(OCH3)-3); 6.82-
7.71 (m, 13H, arom. CHs, NC6H4N, CH2C6H4(OCH3)-3 and
CH2CH2CH2CH2OC6H5); 11.78 (s, 1H, NCHN) ppm. 13C NMR
o
(125 MHz, CDCl3, 25 C): δ = 26.1 (CH2CH2CH2CH2OC6H5);
26.4 (CH2CH2CH2CH2OC6H5); 47.4 (CH2CH2CH2CH2OC6H5);
51.3 (CH2C6H4(OCH3)-3); 55.6 (CH2C6H4(OCH3)-3); 66.7
(CH2CH2CH2CH2OC6H5); 113.1, 113.8, 114.4, 114.8, 120.4,
120.8, 127.2, 129.5, 130.4, 131.2, 131.5, 134.3, 158.5, 160.2
(arom.
Cs,
NC6H4N,
CH2C6H4(OCH3)-3
and
4.3.3. cis/trans-Dichloro-bis[1-(3-methoxybenzyl)-3-(benzyl)benz
imidazol-2-ylidene]palladium(II) (2c)
CH2CH2CH2CH2OC6H5); 143.5 (NCHN) ppm. Elemental
analysis calcd (%) for C25H27ClN2O2 (Mr = 422.90): C 70.99, H
6.43, N 6.62; found (%): C 71.02, H 6.44, N 6.63.
(0.246 g, yield 59%) 1H NMR (400 MHz, CDCl3, 25 oC): δ =
3.61 and 3.62 (s, 6H, CH2C6H4(OCH3)-3); 5.92 and 5.94 (s, 4H,
CH2C6H5); 5.95 and 5.97 (s, 4H, CH2C6H4(OCH3)-3); 6.71-7.39
(m, 26H, arom. CHs, NC6H4N, CH2C6H4(OCH3)-3 and CH2C6H5)
4.3. General procedure for the preparation of palladium(II)-
NHC complexes (2a-f)
o
All benzimidazolium chlorides were converted, with
moderated yields, into the palladium(II)-NHC complexes (2a-f).
A suspension of the benzimidazolium chloride (1.0 mmol) and
ppm. 13C NMR (100 MHz, CDCl3, 25 C): δ = 52.7 and 52.8
(CH2C6H5); 52.9 and 53.0 (CH2C6H4(OCH3)-3); 55.6 and 55.7
(CH2C6H4(OCH3)-3); 111.3, 111.4, 114.5, 114.7, 120.2, 120.3,